The June 1, 2019, article by Walker et al, entitled “Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study” (J Clin Oncol 37:1380-1390, 2019), was published with an error.

In the Results section, under the subheading Efficacy, the second sentence of the third paragraph read: “In this subgroup of patients, the median duration of PFS was 35.9 months for IV carboplatin, 38.8 months for IP carboplatin, and 36.5 months for IP cisplatin.”

It should have read: “In this subgroup of patients, the median duration of PFS was 35.9 months for IV carboplatin, 38.8 months for IP carboplatin, and **35.5** months for IP cisplatin.”

In the fifth paragraph of the Discussion section, the first sentence read: “All arms of the current study compare favorably with hyperthermic IP chemotherapy where the PFS was 14.2 months and OS 33.9 months for patients with stage III resected to 1 cm or less disease.²⁶” It should have read: “All arms of the current study compare favorably with hyperthermic IP chemotherapy where the PFS was 14.2 months and OS **45.7** months for patients with stage III resected to 1 cm or less disease.²⁶”

This has been corrected as of July 22, 2019. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.19.01365>

The April 20, 2019, article by Salz et al entitled “Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers” (J Clin Oncol 37:1001-1011, 2019) was published with an error.

In the section entitled Trends in Chronic Opioid Use Over Time Since Diagnosis Among Cancer Survivors, the first sentence under the subheading Colorectal Cancer read “Across all diagnosis years, the percentage of colorectal cancer survivors with chronic opioid use ranged from 2.0% in the first year after the index date to 4.3% 6 years after the index date (Table 2).”

It should have read “Across all diagnosis years, the percentage of colorectal cancer survivors with chronic opioid use ranged from **2.7%** in the first year after the index date to **4.0%** 6 years after the index date (Table 2).”

This has been corrected as of May 24, 2019. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.19.01267>

The July 1, 2018, article by Stilgenbauer et al entitled “Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial” (J Clin Oncol 36:1973-1980, 2019) was published with an error.

In the ACKNOWLEDGMENT section, the following statement should have appeared: “**This project was funded by the NIHR Oxford Biomedical Research Centre BRC.**”

This has been corrected as of February 13, 2019. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.19.00384>